PLEASANT PRAIRIE, Wis. — Eli Lilly and Company has acquired a state-of-the-art injectable medicine manufacturing facility from Nexus Pharmaceuticals LLC.
The acquisition of this FDA-approved facility in Pleasant Prairie further expands Lilly’s global parenteral injectable product manufacturing network and supports increased demand for the company’s medicines.
Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing, expressed optimism about this facility’s new opportunities.
“Integrating this advanced facility into our network will enhance our ability to produce life-saving medicines more efficiently and at a larger scale,” Hernandez stated.
The pharmaceutical company’s manufacturing network continues this mission on a larger scale.
“Eli Lilly’s choice to invest in Pleasant Prairie is a testament to the strategic value of our location and the quality of our workforce,” said Samantha Kerkman, Kenosha County Executive.
She reflected on the facility’s groundbreaking in 2019, heralded as a promising development for the local economy. The project benefited from the Kenosha Area Business Alliance’s High Impact Fund, which underscores the region’s commitment to supporting significant business investments.
Local business leaders are also hailing this development as a milestone.
Nicole Ryf, President of the Kenosha Area Business Alliance, emphasized the competitive advantages that Kenosha County offers.
“Our robust infrastructure, skilled labor pool, and proximity to major metropolitan areas like Chicago and Milwaukee make Kenosha County an attractive place for high-tech manufacturing,” Ryf said. She also commended Nexus Pharmaceuticals for their visionary work and contribution to the community.
This acquisition promises substantial economic benefits for Pleasant Prairie and Kenosha County. The facility is expected to create many high-paying jobs, from production line workers to chemical engineers and quality assurance specialists. Moreover, it is anticipated to attract additional business investments to the area, further strengthening its economic fabric.
Eli Lilly advances village to critical player in biopharmaceutical field
A global pharmaceutical leader like Eli Lilly in Pleasant Prairie also positions the village as a critical player in the biopharmaceutical field. This sector is becoming increasingly important as the world focuses more on healthcare innovation and accessibility.
As operations are set to commence by the end of 2025, the local community is optimistic about the positive changes the facility will bring.
“We are looking forward to seeing how Eli Lilly’s presence will inspire further growth and innovation in our region,” added Kerkman.
This acquisition underscores a larger trend in the pharmaceutical industry, where big players increasingly invest in specialized facilities to ensure a steady supply of critical medications. For Pleasant Prairie, this move by Eli Lilly could be a pivot point towards becoming a hub for pharmaceutical manufacturing, leveraging its strategic location and enhanced capabilities to play a crucial role in the global healthcare ecosystem.
Editor’s note: Elements of this article were generated by ChatGPT.
Local business
Local businesses and nonprofits make up the backbone of our community. The Racine County Eye, which includes the Kenosha Lens, is your local news source that serves our diverse communities. Become a subscriber to stay up-to-date with local news.
Follow us on Facebook: Racine County Eye or Kenosha Lens, and Instagram to make sure you get the latest news.
Racine County Eye and Kenosha Lens – Journalism that serves.
You must be logged in to post a comment.